Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Rituximab (a monoclonal antibody raised against CD20) is used to treat various immune
disorders. In some cases such as treatment of humoral acute rejection of renal transplant,
thrombotic thrombocytopenic purpura, vasculitis or cryoglobulinemia, rituximab is often
associated with plasma exchange. The pharmacokinetic of the rituximab can be affected by
plasma exchange but the knowledge is poor in this matter.
The aim of the study is to explore the influence of plasma exchange on the pharmacokinetic of
rituximab.
The results of this study should conclude if plasma exchange leads to a significant decrease
of plasma concentration of rituximab or not, and if the decreased of the concentration is
associated with a decrease in efficacy.